Is there currently a role for adding venetoclax to a hypomethylating agent (HMA) after failure of single-agent HMA therapy in MDS?

Topics: Hematologic Malignancies • Medical Oncology • Myelodysplastic Syndromes • Hematology

Can results from emerging AML data be extrapolated to high risk MDS populations?

Is there data to guide the choice of continuing the HMA in combination, or simply switching to venetoclax monotherapy?

Answer from: Medical Oncologist at Community Practice

For patients with MDS who have failed single-agent HMAs, there is an intriguing small retrospective series suggesting that adding on Venetoclax at the time of HMA failure can lead to responses (Ball et al., PMID 32589727). Because of the retrospective nature of this publication and the small numbers...

Comments

at Memorial Hospital for Cancer & Allied Diseases
Agree with Dr. @Eytan M. Stein. Due to uncertain b...

Related Questions